Hepatology(Liver, Pancreatic, Gall Bladder)

  • Home
  • Hepatology(Liver, Pancreatic, Gall Bladder)
Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy

Conditions:   Type 1 Diabetes Mellitus;   Pregnancy in Diabetics
Intervention:   Device: Dexcom G6 CGM
Sponsors:   Sansum Diabetes Research Institute;   Harvard John A. Paulson School of Engineering and Applied Sciences;   Mayo Clinic;   Icahn School of Medicine at Mount Sinai
Recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 11, 2018 / by / in
A Randomized Crossover Comparison of Model Predictive Control (MPC) Artificial Pancreas vs. Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) With Different Food Choices in the Outpatient Setting

Condition:   Type 1 Diabetes Mellitus
Intervention:   Device: iAPS
Sponsors:   Sansum Diabetes Research Institute;   Harvard John A. Paulson School of Engineering and Applied Sciences;   Harvard School of Public Health
Not yet recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 10, 2018 / by / in
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Conditions:   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Gallbladder Cancer
Interventions:   Biological: conventional chemotherapy(FORFIRINOX) combined with target agents;   Biological: conventional chemotherapy(FORFIRINOX)
Sponsors:   Shanghai Jiao Tong University School of Medicine;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Ruijin Hospital;   RenJi Hospital;   Eastern Hepatobiliary Surgery Hospital;   Huashan Hospital
Recruiting
ClinicalTrials.gov: Gall Bladder | Recruiting, Not yet recruiting, Available Studies | First posted in the last 100 days

December 8, 2018 / by / in
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Conditions:   Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC);   Pancreatic Ductal Adenocarcinoma
Interventions:   Radiation: Stereotactic Body Radiation (SBRT);   Drug: Nivolumab;   Drug: CCR2/CCR5 dual antagonist;   Drug: GVAX
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Bristol-Myers Squibb
Not yet recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 7, 2018 / by / in
Harms of Hepatocellular Carcinoma Surveillance

Condition:   Carcinoma, Hepatocellular
Interventions:   Other: Prospective Longitudinal Data;   Other: Surveys and Semi-structured Interviews
Sponsors:   University of Texas Southwestern Medical Center;   National Cancer Institute (NCI);   Parkland Health & Hospital System;   Baylor College of Medicine;   Michael Debakey Veterans Affairs Medical Center;   Kaiser Permanente
Not yet recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 5, 2018 / by / in
GENetic Education Risk Assessment and TEsting Study

Condition:   Candidates for Hereditary Pancreatic Cancer Testing
Interventions:   Other: Doxy.me genetic education +/- Color Genomics genetic education;   Other: Color Genomics genetic education
Sponsors:   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   Johns Hopkins University;   University of California, San Diego;   Mayo Clinic;   Weill Cornell Medicine;   Stand Up To Cancer;   Lustgarten Foundation
Not yet recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 4, 2018 / by / in
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Conditions:   Gastrointestinal Cancer;   Pancreatic Cancer;   Gastric Cancer;   Colon Cancer;   Rectal Cancer
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: anti-KRAS G12D mTCR PBL
Sponsor:   National Cancer Institute (NCI)
Recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 2, 2018 / by / in